Literature DB >> 20004531

The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone.

Wlodzimierz Ruka1, Piotr Rutkowski, Tadeusz Morysiński, Zbigniew Nowecki, Marcin Zdzienicki, Donata Makula, Konrad Ptaszyński, Elzbieta Bylina, Urszula Grzesiakowska.   

Abstract

PURPOSE: To assess the outcomes of radiotherapy, in terms of local control and treatment complications, of advanced or difficult giant cell tumors of bone (GCTB) that could not be treated by surgery. METHODS AND MATERIALS: Among 122 consecutive patients with confirmed GCTB from 1985 to 2007, 77 patients were treated by megavoltage radiotherapy because they were inappropriate candidates for surgery. We have performed analysis of all data in terms of progression-free survival (PFS) and treatment morbidity. Median follow-up time was 58 months.
RESULTS: In the irradiated group, maximal tumor size ranged from 5 to 18 cm (median, 8.5). Anatomic distribution was as follows: femur, 27 cases; tibia, 19; radial/ulnar bone, 12; sacrum, 9; pelvic bones, 5; other, 5. Twenty-one patients (27%) were referred for local recurrence after ≥1 other treatment procedures. The radiation doses ranged from 26 to 89 Gy (median, 56; administered 1.8-2.0 Gy/fraction with average total duration of treatment of 5-7 weeks); 8 patients (10%) received <50 Gy. All patients tolerated treatment well without acute or late complications. All patients except two are alive. Local control was achieved in 65 patients (84%; bone recalcification/restitution of joint functions), 12 patients showed signs of local progression, all within irradiated fields (9 were treated successfully with salvage surgery). Five- and 10-year local PFS were 83% and 73%, respectively. Three patients developed lungs metastases. Malignant transformation of GCTB occurred in two patients.
CONCLUSIONS: GCTB can be safely and effectively treated with megavoltage radiotherapy with local control rate >80% at 5 years. Our study confirms that radiotherapy of GCTB offers an alternative to difficult or complex surgery and may be an option of choice in the treatment of inoperable patients. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20004531     DOI: 10.1016/j.ijrobp.2009.07.1704

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  26 in total

1.  Management of giant cell tumor of bone: computerized tomography based selection strategy and approaching the lesion through the site of cortical break.

Authors:  Dominic K Puthoor; Kishore Puthezhath
Journal:  Orthop Surg       Date:  2012-05       Impact factor: 2.071

Review 2.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

Review 3.  Giant cell tumor of bone: current treatment options.

Authors:  Keith M Skubitz
Journal:  Curr Treat Options Oncol       Date:  2014-09

Review 4.  Integration of denosumab therapy in the management of giant cell tumors of bone.

Authors:  Daniel T Miles; Ryan T Voskuil; Wood Dale; Joel L Mayerson; Thomas J Scharschmidt
Journal:  J Orthop       Date:  2020-03-28

5.  Clival giant cell tumor presenting with isolated trigeminal nerve involvement.

Authors:  Soumyajit Roy; Nikhil P Joshi; Elanthenral Sigamani; Anita Malik; Meher C Sharma; Bidhu K Mohanti; Suresh C Sharma
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-11-10       Impact factor: 2.503

Review 6.  Denosumab and giant cell tumour of bone-a review and future management considerations.

Authors:  S F Xu; B Adams; X C Yu; M Xu
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

Review 7.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

8.  Advantages of Pressurized-Spray Cryosurgery in Giant Cell Tumors of the Bone.

Authors:  Nevzat Dabak; Hasan Göçer; Alper Çıraklı
Journal:  Balkan Med J       Date:  2016-09-01       Impact factor: 2.021

9.  Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine.

Authors:  Ping Jiang; Xile Zhang; Weijuan Jiang; Na Meng; Abudureyimujiang Aili; Junjie Wang
Journal:  Cancer Biol Ther       Date:  2020-04-16       Impact factor: 4.742

10.  Cyberknife stereotactic radiosurgery and denosumab for giant cell tumour of the skull base: Case report.

Authors:  Cuauhtemoc de la Peña; Jorge H Guajardo; Maria F Gonzalez; Miguel A Hinojosa; Erick Cardona
Journal:  Rep Pract Oncol Radiother       Date:  2017-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.